In an effort to normalize the cannabis industry and expand the knowledge available to researchers on the drug itself, a public company with access to a breadth of user data will launch a national study in Canada to evaluate the effects of cannabis treating anxiety.

Namaste Technologies (CSE:N; OTCMKTS:NXTTF) announced on Wednesday (April 4) the launch of its first national research study, titled “Cannabis for Anxiety Reduction study.” The study will, as its title suggests, evaluate the potential of cannabis being used as a treatment for anxiety disorders.

Sean Dollinger, president, and CEO of Namaste said he believes studies like this one will attract more patients to Namaste. After the markets closed on Wednesday, Namaste increased its share value by 10.34 percent and closed valued at C$1.60 for a share.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

“We plan to undertake additional studies to bring awareness and a better understanding of how medical cannabis can benefit Canadians,” he said.

Namaste revealed it planned to conduct more studies, similar to this initial one in the future. However, the company did not disclose what kind of conditions it intends to investigate treating with cannabis.

In order to be considered for the study, Namaste asks that patients must be over 25 years and have a score of eight or above in the Hospital Anxiety and Depression Scale (HADS). The scale, according to studies, provides a helpful initial diagnosis and serves to track the progression of psychological symptoms.

Namaste said the results from the study may be published in a medical publication at a later date. According to the company, the study will take place during a three month period for each patient.

“The study will be submitted for approval to the Veritas Independent Review Board (IRB) prior to commencement,”  the company said.

In March Dollinger told the Investing News Network (INN) he had not decided just how the company would monetize the data it was collecting through its NamasteMD platform. “Right now we believe the most important thing is collecting that data for future use.”

Need for more cannabis research crucial, experts agree

Last year Dave Berg, chief technology officer for a software company, Strainprint–a company with a focus on the cannabis industry–told INN the lack of sophisticated research about the drug has impacted the development of novel therapies for patients using cannabis.

“[I]t’s been very difficult for people to study cannabis in a clinical way, but there’s been a ton observational data… There’s no really strong observational data set that allows us to make proper decisions,” Berg said.

Despite the lack of current research David Argudo, CEO of High Hampton Holdings (CSE:HC) said the wait for sophisticated data will not take a long amount of time

“I think we are going to see more [cannabis research data] even sooner than 15 years,” Argudo told INN when asked if he expects the amount of cannabis research to increase over that period.

Government support for research is coming in Canada

As part of its endeavor on the legalization of cannabis, the Canadian government announced it will be spending C$20 million for cannabis research as indicated in its 2018 budget.

The money will be split with C$10 million going to the Mental Health Commission to “assess the impact of cannabis use on the mental health of Canadians.”

The remaining C$10 million will go to the Canadian Centre on Substance Use and Addiction for general research purposes. Both sums will be given over five years.

Don’t forget to follow us @INN_Cannabis  for real-time news updates! 

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: High Hampton Holdings is a client of the Investing News Network. This article is not paid-for content.


Cannabis - Will The Fortune 500 Join The Party?

Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a new Florida dispensary, the Company’s 91st nationwide.

The latest dispensary, located in Winter Park , supports Trulieve’s goal of ensuring medical cannabis patients across Florida have safe, reliable access to the medications they rely on. The dispensary expands access throughout Central Florida , joining four locations throughout nearby Orlando .

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis extractor, is pleased to announce that the United States Patent and Trademark Office has granted the Company a patent pertaining to the extraction and purification of THC and CBD.

The Company believes it has developed defendable intellectual property around the most efficient methods for producing THC and CBD distillate at scale within a regulated market. Nextleaf owns 15 U.S. patents and has been issued over 80 patents globally.

Keep reading... Show less

Cannabis Company Executives share vision, answer questions live at

Virtual Investor Conferences in partnership with KCSA Strategic Communications and ATB Capital Markets today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The two-day program begins at 9:30 AM ET on Tuesday June 29 th .

Keep reading... Show less

Acquisition solidifies Canopy Growth’s leadership position in the Canadian recreational market

Canopy Growth Corporation (“Canopy”) (TSX: WEED) (NASDAQ: CGC) and The Supreme Cannabis Company, Inc. (“Supreme”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) are pleased to announce the completion of the previously announced arrangement (the “Arrangement”) whereby Canopy has acquired all of the issued and outstanding common shares of Supreme (the “Supreme Shares”).

Keep reading... Show less